Drug Profile
Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories
Alternative Names: Allo iPS cell-derived retinal pigment epithelium; Cell therapies for ophthalmic diseases - Shin Nippon Biomedical Laboratories (SNBL)/RIKEN; Induced pluripotent stem (iPS) cells for eye disorders - Shin Nippon Biomedical Laboratories; iPS cell-derived RPE cell transplantation for Age-related macular degeneration - Healios/Shin Nippon Biomedical Laboratories; iPSC-derived RPE sheet - RIKEN/Healios; Retinal pigment epithelial (RPE) cells for AMD - Healios/RIKENLatest Information Update: 16 Feb 2023
Price :
$50
*
At a glance
- Originator RIKEN
- Developer Healios; RIKEN; Shin Nippon Biomedical Laboratories
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration
- No development reported Eye disorders
Most Recent Events
- 31 Jan 2023 Preclinical development is still ongoing for Age-related macular degeneration in Japan (Intraocular)
- 31 Jan 2023 Sumitomo Pharma plans a clinical trial for Age-related macular degeneration in Japan (Intraocular) in 2022
- 28 Jul 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Intraocular, Injection)